Island Pharmaceuticals Ltd has released a press release.
Grant funding to directly support Phase 2a trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Investor Presentation - Asia Bio Partnering
- Positive data from ISLA-101 Single Ascending Dose study
- Security Class Reinstatement to Quotation ILAO
- Security Class Suspension from Quotation ILAO
- Island Pharmaceuticals to raise $1.95 million for ISLA-101 development
Later from Island Pharmaceuticals
- New data leads to proposed ISLA-101 Phase 2 efficiencies
- Investor Presentation
- Non-binding term sheet signed with BioCryst
- ISLA-101 Phase 2a/b clinical trial progresses
- Binding LOI for proposed acquisition of Galidesivir
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals